ANTABUSE (disulfiram) by Molecular Devices is clinical pharmacology: disulfiram produces a sensitivity to alcohol which results in a highly unpleasant reaction when the patient under treatment ingests even small amounts of alcohol. Approved for aldehyde dehydrogenase inhibitor [epc]. First approved in 1983.
Drug data last refreshed 18h ago
CLINICAL PHARMACOLOGY: Disulfiram produces a sensitivity to alcohol which results in a highly unpleasant reaction when the patient under treatment ingests even small amounts of alcohol. Disulfiram blocks the oxidation of alcohol at the acetaldehyde stage. During alcohol metabolism following…
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Treatment of Advance Gastric Cancer With Disulfiram
Study of Disulfiram and Copper Gluconate in Patients With Treatment-Refractory Multiple Myeloma
Disulfiram-Copper Gluconate in Met Pancreas Cancer w Rising CA19-9 on Abraxane-Gemzar, FOLFIRINOX or Gemcitabine
Combination Latency Reversal With High Dose Disulfiram Plus Vorinostat in HIV-infected Individuals on ART
A Phase Ib Study of Intravenous Copper Loading With Oral Disulfiram in Metastatic, Castration Resistant Prostate Cancer
Worked on ANTABUSE at Molecular Devices? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.